The tariff classification of Duloxetine Hydrochloride Delayed-Release Capsules in dosage form, from India
Reasoning
The tariff classification of Duloxetine Hydrochloride Delayed-Release Capsules in dosage form, from India
Cite this ruling
CBP Ruling N332805 (3004909235): The tariff classification of Duloxetine Hydrochloride Delayed-Release Capsules in dosage form, from India
Paste this into a product's override reason when citing this ruling as justification for a classification.
Other rulings for HS6 300490
The tariff classification of dietary supplements from Italy
The tariff classification of IQUIX® (levofloxacin ophthalmic solution) 1.5%, imported in bulk and measured-dose forms, from Finland
The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use
The tariff classification of Pulmozyme® (dornase alfa) Inhalation Solution; Raptiva® (Efalizumab) for injection, subcutaneous; Rituxan® (Rituximab); TNKase™ (Tenecteplase); and Xolair® (Omalizumab) for subcutaneous use
The tariff classification of Activase® (Alteplase recombinant), Avastatin™ (bevacizumab), Cathflo™Activase® (Alteplase) and Herceptin® (Trastuzumab)